2b or NOT to be, page-84

First 84 Last

Share
Profile

Follow
Gan_Gans

2,129 Posts.

569

01/09/22

10:06

Post #: 63454612
Share

Originally posted by Denial: ↑

It was noted back to PAR to consider rather than seeking explanation on disclosure as we recognized the inherent complexity with intangible disclosure standards. Agree other peer bios probably do a better job listing all intangibles (both patents and IP protection). The golden goose is our exclusivity agreement with Bene and yet also not listed.

I would encourage you to follow-up directly beforehand to help clarify their future accounting treatment intent in this space.

On a separate but related note what is also apparent to me now from Iken's post above is the suggestion that PAR may be "ever-greening" patents due to a study back in 1972 that identified PPS effect on cartilage. What this term refers to is using loopholes in the patent law to make small changes such as through modes of administration or new dosages. The intent is naturally to create a defensive business strategy to avoid competition and earn outsized profits. However, this accusation could be levelled against any biopharma given that fact that ~80% of drugs associated with new patents are not new drugs rather existing ones. This law is unlikely to change anytime soon given there needs to be strong incentive to risk the upfront costs associated with R&D and innovation.

What PAR is doing with attempting to broaden their patent applications is to provide an additional layer of assurance, in additional to the barriers created via Bene exclusivities. Whether this strategy is in fact accreditive when it comes to signing a deal is a TBA.

If PPS proves to be as effective as currently indicated on pain, function and duration there appears to be plenty of room for future competition with or without patent protect for all of us to reap a significant windfall. And big pharma will be looking at it from the prospect of distributing it as a DMOAD "grand slam" blockbuster given no biosimilar generic is realistically attainable.

Expand

Thank you.

There is a note in the Annual Report on how they treat patents in intangibles, noting they are carried when the patents are "considered held ready for use" - on cost basis less amort. Those "foundational' patents did cost the company, including 3 million shares to the inventor that assigned the patent to Paradigm, (and family still listed in the top 20)

PAR Price at posting: $1.29 Sentiment: Buy Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

LML

Lincoln repositions Kookaburra for low-cost graphite delivery

POL

Polymetals finalises acquisition of Endeavor silver-lead-zinc mine in NSW's Cobar Basin

MAG

Magmatic defines 6km copper trend with grades of up to 6.5% at NSW prospect

AVH

Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin

WCN

White Cliff wraps up Canadian fieldwork programs – 'visually confirming' a slew of minerals

There are more pages in this discussion • 1 more message in this thread...

First 84 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change 0.005(2.04%)		Mkt cap ! $87.44M

Open	High	Low	Value	Volume
24.5¢	25.0¢	24.5¢	$8.544K	34.18K

Buyers (Bids)

No.	Vol.	Price($)
5	42919	25.0¢

Sellers (Offers)

Price($)	Vol.	No.
25.5¢	11500	2

View Market Depth

No.	Vol.	Price($)
3	17819	0.250
14	174685	0.245
10	146400	0.240
5	118253	0.235
7	158282	0.230

Price($)	Vol.	No.
0.255	1500	1
0.260	39818	5
0.265	51487	2
0.270	20000	2
0.275	13099	3

Last trade - 10.29am 01/08/2024 (20 minute delay)

PAR (ASX) Chart

2b or NOT to be, page-84

Lincoln repositions Kookaburra for low-cost graphite delivery

Polymetals finalises acquisition of Endeavor silver-lead-zinc mine in NSW's Cobar Basin

Magmatic defines 6km copper trend with grades of up to 6.5% at NSW prospect

Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin

White Cliff wraps up Canadian fieldwork programs – 'visually confirming' a slew of minerals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

2b or NOT to be, page-84

Top Stories

Lincoln repositions Kookaburra for low-cost graphite delivery

Polymetals finalises acquisition of Endeavor silver-lead-zinc mine in NSW's Cobar Basin

Magmatic defines 6km copper trend with grades of up to 6.5% at NSW prospect

Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin

White Cliff wraps up Canadian fieldwork programs – 'visually confirming' a slew of minerals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News